A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Status:
Recruiting
Trial end date:
2027-08-16
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out if the combination of avutometinib and
defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory
differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test
whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.